Brain and Nervous System, Phase II-III
GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
Volunteers
Health Professionals
What is the purpose of this trial?
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Alison Johnson
- Andrea Brennan
- Antonio Omuro, MD
- Catherine Wei, MD
- Clarice Grens
- David Witt, MD
- Harold Tara Jr, MD
- Jaykumar Thumar, MBBS, MD
- Joachim Baehring, MD
- Justin Persico, MD
- Larisa Fleysher
- Madeline Santiago
- Mary Michele Barden, MD
- Matthew Dodd, PA-C
- Michael Cohenuram, MD
- Neal Fischbach, MD
- Nicholas Blondin, MD
- Renee Moye
- Vanessa Nevins, PA-C
- Last Updated04/18/2024
- Study HIC#2000026339